Stock Track | DaVita HealthCare Partners Soars 14.52% in After-Hours Trading on Strong Q4 Earnings Beat and Upbeat 2026 Guidance

Stock Track09:08

DaVita HealthCare Partners Inc. (DVA) experienced a significant surge of 14.52% in after-hours trading on Monday. The sharp upward movement followed the release of the company's fourth-quarter financial results and optimistic outlook for the coming year.

The dialysis services provider reported adjusted earnings per share of $3.40 for Q4 2025, surpassing analyst estimates. Revenue for the quarter reached $3.62 billion, also exceeding expectations. More importantly, DaVita provided 2026 adjusted EPS guidance in the range of $13.60 to $15.00, significantly above the consensus estimate, signaling management's confidence in future performance driven by steady demand for kidney dialysis services.

Additional factors contributing to positive sentiment include higher reimbursement rates, a favorable impact from flu vaccines, and the company's recovery from prior operational challenges. DaVita also announced a strategic investment in home care provider Elara Caring to co-develop a kidney-specific home-based care model, supporting its growth initiatives in personalized patient care.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117361080?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 09:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117361080","market":"us","top_or_hot":-1,"title":"Stock Track | DaVita HealthCare Partners Soars 14.52% in After-Hours Trading on Strong Q4 Earnings Beat and Upbeat 2026 Guidance","media":"Stock Track","content":"<p>DaVita HealthCare Partners Inc. (DVA) experienced a significant surge of 14.52% in after-hours trading on Monday. The sharp upward movement followed the release of the company's fourth-quarter financial results and optimistic outlook for the coming year.</p><p>The dialysis services provider reported adjusted earnings per share of $3.40 for Q4 2025, surpassing analyst estimates. Revenue for the quarter reached $3.62 billion, also exceeding expectations. More importantly, DaVita provided 2026 adjusted EPS guidance in the range of $13.60 to $15.00, significantly above the consensus estimate, signaling management's confidence in future performance driven by steady demand for kidney dialysis services.</p><p>Additional factors contributing to positive sentiment include higher reimbursement rates, a favorable impact from flu vaccines, and the company's recovery from prior operational challenges. DaVita also announced a strategic investment in home care provider Elara Caring to co-develop a kidney-specific home-based care model, supporting its growth initiatives in personalized patient care.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | DaVita HealthCare Partners Soars 14.52% in After-Hours Trading on Strong Q4 Earnings Beat and Upbeat 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | DaVita HealthCare Partners Soars 14.52% in After-Hours Trading on Strong Q4 Earnings Beat and Upbeat 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-03 09:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DaVita HealthCare Partners Inc. (DVA) experienced a significant surge of 14.52% in after-hours trading on Monday. The sharp upward movement followed the release of the company's fourth-quarter financial results and optimistic outlook for the coming year.</p><p>The dialysis services provider reported adjusted earnings per share of $3.40 for Q4 2025, surpassing analyst estimates. Revenue for the quarter reached $3.62 billion, also exceeding expectations. More importantly, DaVita provided 2026 adjusted EPS guidance in the range of $13.60 to $15.00, significantly above the consensus estimate, signaling management's confidence in future performance driven by steady demand for kidney dialysis services.</p><p>Additional factors contributing to positive sentiment include higher reimbursement rates, a favorable impact from flu vaccines, and the company's recovery from prior operational challenges. DaVita also announced a strategic investment in home care provider Elara Caring to co-develop a kidney-specific home-based care model, supporting its growth initiatives in personalized patient care.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVA","symbol_name":"达维塔保健","start_time":0,"source_url":"","article_id":"1117361080","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117361080","pubTimestamp":1770080934,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"DaVita HealthCare Partners Inc. (DVA) experienced a significant surge of 14.52% in after-hours trading on Monday. The sharp upward movement followed the release of the company's fourth-quarter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DVA":"达维塔保健"},"translate_title":"股票追踪|DaVita HealthCare Partners因强劲的第四季度盈利和乐观的2026年指引而在盘后交易中飙升14.52%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVA":1},"content_text":"DaVita HealthCare Partners Inc. (DVA) experienced a significant surge of 14.52% in after-hours trading on Monday. The sharp upward movement followed the release of the company's fourth-quarter financial results and optimistic outlook for the coming year.The dialysis services provider reported adjusted earnings per share of $3.40 for Q4 2025, surpassing analyst estimates. Revenue for the quarter reached $3.62 billion, also exceeding expectations. More importantly, DaVita provided 2026 adjusted EPS guidance in the range of $13.60 to $15.00, significantly above the consensus estimate, signaling management's confidence in future performance driven by steady demand for kidney dialysis services.Additional factors contributing to positive sentiment include higher reimbursement rates, a favorable impact from flu vaccines, and the company's recovery from prior operational challenges. DaVita also announced a strategic investment in home care provider Elara Caring to co-develop a kidney-specific home-based care model, supporting its growth initiatives in personalized patient care.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117361080","isCrawlerRequest":true}